Cardiac diagnostics and monitoring
CRYSTAL-AF study
The Reveal LINQ™ insertable cardiac monitor (ICM) is superior to standard monitoring for AF detection in cryptogenic stroke patients.1
The primary end point is the time to first detection of AF at six months of follow-up.
The landmark CRYSTAL-AF study found that continuous monitoring with the Reveal LINQ™ ICM is superior to standard monitoring for detection of atrial fibrillation (AF or AFib) in patients with a cryptogenic stroke.1
30% AF detected at three years versus 3% for standard of care:
At 12 months, 97% of patients in whom AF was detected received oral anticoagulant.
79% of first AF episodes were asymptomatic at 12 months.
Detection of AF by 36 months
Hazard ratio, 8.8 (95% CI, 3.5–22.2) p < 0.001 by log-rank test
† Based on Kaplan-Meier estimates.
“Atrial fibrillation after cryptogenic stroke was most often asymptomatic and paroxysmal and thus unlikely to be detected by strategies based on symptom-driven monitoring or intermittent short-term recordings.”1
Watch webinars on secondary stroke prevention and the role of insertable cardiac monitoring.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.